These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 20688181

  • 1. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, Sy S, Roa L, Khan F, Fonseca K, Russell JA, Storek J.
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
    [Abstract] [Full Text] [Related]

  • 2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 3. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2004 Jan 01; 10(1):49-57. PubMed ID: 14752779
    [Abstract] [Full Text] [Related]

  • 4. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
    Mikulska M, Raiola AM, Bruzzi P, Varaldo R, Annunziata S, Lamparelli T, Frassoni F, Tedone E, Galano B, Bacigalupo A, Viscoli C.
    Biol Blood Marrow Transplant; 2012 Jan 01; 18(1):92-9. PubMed ID: 21689774
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T, Dunne J, Crowley B.
    J Med Virol; 2010 Mar 01; 82(3):433-40. PubMed ID: 20087937
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.
    Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, Garcia-Noblejas A, Clari MA, Chilet M, López J, Hernández-Boluda JC, Remigia MJ, Navarro D.
    J Med Virol; 2010 Jul 01; 82(7):1208-15. PubMed ID: 20513086
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
    Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, Frommlet F, Gadner H, Peters C.
    Bone Marrow Transplant; 2003 May 15; 31(9):803-8. PubMed ID: 12732888
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors.
    Hoegh-Petersen M, Roa L, Liu Y, Zhou F, Ugarte-Torres A, Louie P, Fonseca K, Khan F, Russell JA, Storek J.
    Cytotherapy; 2012 Feb 15; 14(2):194-204. PubMed ID: 22149135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.